VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 29,000 Shares of Vaxcyte, Inc. $PCVX

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 29,000 shares of the company’s stock, valued at approximately $1,650,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Jupiter Topco LLC bought a new position in shares of Vaxcyte during the 2nd quarter worth about $1,044,355,000. Janus Henderson Group PLC raised its position in Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. BlackRock Inc. acquired a new position in Vaxcyte in the second quarter worth about $701,520,000. Wellington Management Group LLP raised its position in Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock worth $407,001,000 after purchasing an additional 1,386,968 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Vaxcyte by 150.6% during the first quarter. Jennison Associates LLC now owns 1,698,011 shares of the company’s stock worth $98,671,000 after purchasing an additional 1,020,458 shares during the period. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. BTIG Research restated a “buy” rating and issued a $89.00 price objective on shares of Vaxcyte in a report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Guggenheim upped their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $120.00 price target on shares of Vaxcyte in a research note on Monday, October 12th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $110.50.

Insider Activity at Vaxcyte

In other news, EVP Jim Wassil sold 2,250 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $60.90, for a total value of $137,025.00. Following the transaction, the executive vice president owned 145,435 shares in the company, valued at $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $60.92, for a total value of $182,760.00. Following the sale, the chief accounting officer owned 27,860 shares of the company’s stock, valued at $1,697,231.20. This trade represents a 9.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 50,692 shares of company stock valued at $4,032,875. Company insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $65.68 on Thursday. The company’s 50 day moving average price is $61.64 and its two-hundred day moving average price is $57.16. Vaxcyte, Inc. has a 52 week low of $39.87 and a 52 week high of $90.75.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same period in the prior year, the business posted ($1.56) earnings per share. On average, analysts predict that Vaxcyte, Inc. will post -7.47 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.